Scholarlink

<p>Epidemiological evidence support the idea that CST I, <i>L. crispatus</i>-dominated vaginal microbiota, could protect women form cervical HPV infection also favoring the HPV clearance. Our prospective, multi-center, randomized, placebo-controlled trial on 62 women newly diagnosed of HPV infection without visible cervical lesions at colposcopy, was mainly aimed at evaluating the role exerted by the oral treatment (daily, 4 months) with the strain <i>L. crispatus</i> M247 in prompting the HR-HPV clearance and CST shift. The results of our study demonstrated that the probiotic treatment significantly increased versus control: (i) the HPV clearance (60% versus 31.8%), and (ii) the number of negative PAP tests (83.3% versus 71.4%), favoring also the vaginal microbiota eubiosis. Particularly, the vaginal microbiota analysis demonstrated a significant relationship between the observed HPV clearance and: (i) a reduced richness; (ii) an increased relative presence of <i>L. crispatus</i>; and (iii) an increased number of women with a CST I microbiota. While a larger study would further strengthen these findings, the current evidence provides encouraging insights into the potential efficacy of the oral treatment with the strain <i>L. crispatus</i> M247.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effect of orally administered L. crispatus M247 in favoring HR-HPV clearance and CST shift: results from a randomized, multi-center, placebo-controlled trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月22日

查看全文
  • Francesco Di Pierro,
  • Emanuela Gloria Sampugnaro,
  • Giovanna Erika Lomeo,
  • Maria Francesca Guarneri,
  • Stefania Cusenza,
  • Alessia Pivetti,
  • Amjad Khan,
  • Fazle Rabbani,
  • Nazia Mumtaz Memon,
  • Massimiliano Cazzaniga,
  • Alexander Bertuccioli,
  • Mariarosaria Matera,
  • Ilaria Cavecchia,
  • Martino Recchia,
  • Chiara Maria Palazzi,
  • Maria Laura Tanda,
  • Nicola Zerbinati,
  • Emilio Lomeo

摘要

Epidemiological evidence support the idea that CST I, L. crispatus-dominated vaginal microbiota, could protect women form cervical HPV infection also favoring the HPV clearance. Our prospective, multi-center, randomized, placebo-controlled trial on 62 women newly diagnosed of HPV infection without visible cervical lesions at colposcopy, was mainly aimed at evaluating the role exerted by the oral treatment (daily, 4 months) with the strain L. crispatus M247 in prompting the HR-HPV clearance and CST shift. The results of our study demonstrated that the probiotic treatment significantly increased versus control: (i) the HPV clearance (60% versus 31.8%), and (ii) the number of negative PAP tests (83.3% versus 71.4%), favoring also the vaginal microbiota eubiosis. Particularly, the vaginal microbiota analysis demonstrated a significant relationship between the observed HPV clearance and: (i) a reduced richness; (ii) an increased relative presence of L. crispatus; and (iii) an increased number of women with a CST I microbiota. While a larger study would further strengthen these findings, the current evidence provides encouraging insights into the potential efficacy of the oral treatment with the strain L. crispatus M247.